A reporter from the Star Daily learned at the site of the tenth batch of pharmaceutical collective procurement that the highly competitive Sitagliptin had over 30 companies bidding, including Zhejiang Huahai Pharmaceutical, Sichuan Kelun Pharmaceutical, Chia Tai Tianqing, Tonghua Dongbao Pharmaceutical, Zhejiang Medicine, Hunan Jiudian Pharmaceutical, Shiyao Ouyi, and Cisen Pharmaceutical among others. From the bidding results, the lowest winning bid price has already fallen to below 0.2 yuan per tablet, a reduction of over 90% from the price limit. Statistics show that this product's sales in public medical institutions in China exceeded 2 billion yuan in 2023, with the original manufacturer Merck accounting for over 90% of the sales, indicating a large space for generic drug replacement. This time, Merck's quote was around 7.37 yuan per tablet. (Reporter Xu Hong)